Adenovirus keratoconjunctivitis after LASIK as a complication of COVID-19 vaccination: a clinical case
https://doi.org/10.21516/2072-0076-2024-17-1-95-99
Abstract
During large-scale vaccination against coronavirus infection, studying possible side effects after the introduction of the vaccine is of great practical value. We present a rare clinical case of a complication of COVID-19 vaccine prophylaxis. A 40-year-old female patient was diagnosed with a bilateral adenoviral keratoconjunctivitis complicated by corneal erosion and iritis after a LASIK refractive intervention and a subsequent (after 5 days) immunoprophylaxis with the Gam-COVID-Vac vaccine followed by a displacement of the corneal flap due to involuntary friction of the left eye. The corneal flap was urgently repositioned; its adhesion and stabilization were achieved usinga bandage soft contact lens. The timely local and systemic anti-inflammatory and antiviral therapy allowed achieving a successful visual result (1.0). Ophthalmologists need to remain vigilant about possible adverse effects after immunoprophylaxis on the part of the eye, specifically the conjunctiva and cornea. A timely diagnosis and treatment are important to prevent complications such as persistent corneal opacities that reduce visual acuity, especially in patients who have undergone refractive surgery aimed at achieving the highest possible vision. In our opinion, it is advisable to perform vaccination at least 1 month after the refractive surgery.
About the Authors
A. E. BabushkinRussian Federation
Alexander E. Babushkin — Dr. of Med. Sci., head of research department
90, Pushkin street, Ufa, 450008
G. Z. Israfilova
Russian Federation
Gulnara Z. Israfilova — methodologist
90, Pushkin street, Ufa, 450008
G. R. Saitova
Russian Federation
Gulnaz R. Saitova — ophthalmologist of the consultative polyclinic department
90, Pushkin street, Ufa, 450008
R. I. Khikmatullin
Russian Federation
Renat I. Khikmatullin — ophthalmologist of the outpatient department
90, Pushkin street, Ufa, 450008
References
1. Kumar A, Dowling WE, Rom n RG, et al. Status report on COVID-19 vaccines development. Curr Infect Dis Rep. 2021; 23 (6): 9. doi: 10.1007/s11908-021-00752-3
2. Starodubov V.I., Kadyrov F.N., Obukhova O.V, Nesvetaylo N.Ya., Endovitskaya Yu.V. The impact of the coronavirus COVID-19 on the situation in Russian healthcare. Health manager. 2020; 4: 58–71 (In Russ.)
3. Babushkin A.E., Israfilova G.Z., Saitova G.R. A case of the development of Lyell's syndrome in a patient after vaccination for coronavirus infection COVID-19. Point of view. East — West. 2022; 1: 68–74 (In Russ.) doi: 10.25276/2410-1257-2022-1-68-74
4. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021; 384 (15): 1412–23. doi:10.1056/NEJMoa2101765
5. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396 (10249): 467–78. doi:10.1016/S0140-6736(20)31604-4
6. Palacios R, Pati o EG, de Oliveira Piorelli R, et al. Double-blind, randomized, placebo-controlled phase III clinical rial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac-PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020; 21 (1): 853. doi: 10.1186/s13063-020-04775-4
7. Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021: NEJMoa2107659. doi:10.1056/NEJMoa2107659
8. Onishchenko G.G., Sizikova T.E., Lebedev V.N., Borisevich S.V. Comparative characteristics of vaccines against COVID-19 used in mass immunization. BIOpreparations. Prevention, diagnosis, treatment. 2021; 21 (3): 158–66 (In Russ.)]. doi: 10.30895/2221-996X-2021-21-3-158-166
9. Shchelkanov M. Yu., Anan'ev V.Yu., Kuznetsov V.V., Shumatov V.B. Middle East respiratory syndrome: when will the smoldering fire erupt? Pacific medical journal. 2015; 2 (60): 94–8 (In Russ.)
10. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396: 887–97.
Review
For citations:
Babushkin A.E., Israfilova G.Z., Saitova G.R., Khikmatullin R.I. Adenovirus keratoconjunctivitis after LASIK as a complication of COVID-19 vaccination: a clinical case. Russian Ophthalmological Journal. 2024;17(1):95-99. (In Russ.) https://doi.org/10.21516/2072-0076-2024-17-1-95-99